Sugi Predict

Sugi Predict / Compounds / SCHEMBL2912604

SCHEMBL2912604

SCHEMBL2912604

Cc1c(Br)cccc1COc1ccc(C=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.48
▸ RAB9A P51151 4/20 0.48
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ NPC1 O15118 3/20 0.48
▸ MAPT P10636 2/20 0.48
▸ HTT P42858 1/20 0.48
▸ KDM4E B2RXH2 3/20 0.46
▸ PARP10 Q53GL7 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ LMNA P02545 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ FFAR1 O14842 1/20 0.41
▸ FFAR4 Q5NUL3 1/20 0.41
▸ MAOB P27338 5/20 0.40
▸ MAOA P21397 4/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ CYP2A6 P11509 1/20 0.40
▸ CCNB2 O95067 1/20 0.39
▸ CDK1 P06493 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15774723 0.84 ALDH1A1 (0.59) ALDH1A1RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL2026505 0.82 KDM4E (0.46) ALDH1A1RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL30577145 0.80 POLB (0.50) ALDH1A1RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL20540272 0.80 POLB (0.50) ALDH1A1RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL12578021 0.79 FFAR1 (0.61) ALDH1A1RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL30336746 0.79 ALDH1A1 (0.57) ALDH1A1RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL28617128 0.79 ALDH1A1 (0.57) ALDH1A1RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL498283 0.78 MAOB (0.60) ALDH1A1RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL13117669 0.78 FFAR1 (0.46) ALDH1A1RAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL29724497 0.78 ALDH1A1 (0.51) ALDH1A1RAB9ASMN1; SMN2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590062-B2 PD-1/PD-L1 inhibitors GILEAD SCIENCES, INC. (US) 2026-03-31 — — US disclosed
EP-4026835-A2 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2022-07-13 — — EP disclosed
US-20210323922-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2021-10-21 — — US disclosed
EP-3612525-A1 PD-1/PD-L1 INHIBITORS Gilead Sciences, Inc. (US) 2020-02-26 — — EP disclosed
CN-110799509-A PD-1/PD-L1 inhibitors 吉利德科学公司 2020-02-14 — — CN disclosed
WO-2018195321-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2018-10-25 — — WO disclosed
US-20180305315-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. 2018-10-25 — — US disclosed
US-9872852-B2 Compounds useful as immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-23 — — US disclosed
US-9872852-B2 Compounds useful as immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-23 — — US disclosed
US-9872852-B2 Compounds useful as immunomodulators BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-23 — — US disclosed
US-20160194307-A1 COMPOUNDS USEFUL AS IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2016-07-07 — — US disclosed
WO-2015034820-A1 COMPOUNDS USEFUL AS IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-03-12 — — WO disclosed
WO-2015034820-A1 COMPOUNDS USEFUL AS IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-03-12 — — WO disclosed
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 — — US disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 — — US disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 — — US disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 — — US disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 — — EP disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 — — EP disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323922-A1 PD-1/PD-L1 INHIBITORS CD274, PDCD1, PDCD1LG2 ALDH1A1 104/4885RAB9A 1946/4885SMN1; SMN2 3111/4885
US-20090186909-A1 Oxadiazolidinedione Compound GPR119, GPR39, GPR65 ALDH1A1 3249/4885RAB9A 4056/4885SMN1; SMN2 3411/4885
US-12590062-B2 PD-1/PD-L1 inhibitors CD274, PDCD1LG2, PDCD1 ALDH1A1 409/4885RAB9A 2152/4885SMN1; SMN2 3418/4885
US-20160194307-A1 COMPOUNDS USEFUL AS IMMUNOMODULATORS CD74, HAVCR2, CD4 ALDH1A1 322/4885RAB9A 2180/4885SMN1; SMN2 3367/4885
US-20180305315-A1 PD-1/PD-L1 INHIBITORS CD274, PDCD1, PDCD1LG2 ALDH1A1 104/4885RAB9A 1946/4885SMN1; SMN2 3111/4885
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND GPR119, GLP1R, GPR4 ALDH1A1 2370/4885RAB9A 3697/4885SMN1; SMN2 3468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.